Skip to main
  1. Stocks
  2. Scribe Therapeutics Inc
  3. Forecast
SCTX

SCTX Stock Forecast & Price Target

SCTX Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Scribe Therapeutics is viewed positively because STX-1150 has already shown a compelling preclinical profile, with >50% LDL-C lowering sustained for two years in NHPs, no significant liver-safety signal, and >5x higher potency in human hepatocytes than in cynomolgus cells, suggesting a credible path to low-dose human activity. Its ELXR platform could fill a differentiated niche between chronic PCSK9 drugs and permanent genome editing by preserving DNA sequence while offering the convenience of one infusion and the potential for years of LDL-C control, which directly addresses poor adherence in a market where current PCSK9 therapies still generate about $5.1 billion in annual global sales. Financially, the company appears undervalued relative to strategic precedent, with an estimated enterprise value of about $360 million versus Verve’s $549 million net-cash takeout, while pro forma cash and no debt support runway into 1H29 and funding for the 1H27 readout and initial XE development.

Bears say

Scribe Therapeutics is viewed skeptically because its value depends on first-in-human proof that STX-1150 can translate preclinical promise into durable, safe human efficacy, yet ELXR/XE have no clinical data and the company expects no product revenue in 2026 or 2027. Its balance sheet is not strong enough to eliminate risk, with about $170 million of cash and management guidance only into 1H29, while continued losses, potential dilution, and collaboration revenue of just $11.5 million in FY2026 and $6.7 million in FY2027 underscore the lack of near-term commercialization. Competitive and reimbursement pressures are also severe, as established and advancing PCSK9 and Lp(a) therapies may reach the market first, and Scribe’s one-time IV genetic medicines must prove they can win on efficacy, safety, cost, and adoption.

SCTX has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Scribe Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

SCTX Analyst Forecast & Price Prediction

Get the latest SCTX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in SCTX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Scribe Therapeutics Inc (SCTX) Forecast

Analysts have given SCTX a Buy based on their latest research and market trends.

According to 4 analysts, SCTX has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Scribe Therapeutics Inc (SCTX)


SCTX Analyst Forecast & Price Prediction

Get the latest SCTX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in SCTX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover SCTX stock data and trends